Small-Cap Stocks: Key Influences and Forthcoming Catalysts (CAUD, PERF, NUKK, BIVI, BDRX)

Analyzing five distinct penny stocks for the week requires focusing on potential near-term driving forces, including breakout and resistance levels. Anticipating upward movements and identifying crucial entry points are essential strategies. Exercise patience to mitigate risks associated with potential market lows and wait for confirmation through significant breakout thresholds.

Collective Audience, Inc. (NASDAQ: CAUD) - Collective Audience, Inc. shares ended last week's trading session up 5% at $0.39. In April, the company announced a definitive agreement to acquire DSL Digital, a provider of Marketing-as-a-Service solutions powered by proprietary AI technology. This acquisition is expected to form the foundation of the new AudienceServices™ group. "This key acquisition will provide the foundational professional capabilities and technology for our new AudienceServices group, enhancing our performance advertising strategy, campaign development, media buying, content marketing, and SEO," stated Collective Audience CEO Peter Bordes. "DSL Digital's talented team has developed unique AI-powered performance advertising tools, delivering significantly higher campaign performance for its clients compared to industry averages. We view these tools and services as integral to our AudienceCloud™ infrastructure and ecosystem, furthering our mission to address the challenges in today's digital media and advertising industry." The transaction is expected to close before the end of the current quarter. At the end of May, the company announced that Nasdaq indicated non-compliance with the continued listing requirements due to the delayed filing of its quarterly report on Form 10-Q for the quarter ended March 31, 2024. The company has until June 24, 2024, to submit a plan to regain compliance but anticipates filing the Form 10-Q ahead of the deadline. Additionally, the company announced valuable new board additions, two major partnerships, and two significant acquisitions expected to close in the coming weeks. As we await further updates, we will be watching for a possible resistance break at the $0.42 level.

--

Perfect Corp. (NYSE: PERF) - Perfect Corp. shares ended last week's trading session at $1.82, down 5%. At the end of May, the company announced the return of its annual franchise event, The Global Beauty and Fashion AI Forum, scheduled for Monday, June 24, 2024, in NYC. The event will be held at The Metropolitan Pavilion, 125 West 18th Street, from 11:30 AM to 6:00 PM ET, featuring comprehensive programming with key opinion leaders from the beauty, fashion, technology, retail, and media sectors. This year's theme, "Immerse Yourself in the World of Beautiful AI Innovation," will explore how AI technology is enhancing the beauty and fashion retail experience. The event will unveil Perfect Corp.'s newly developed AI assistant framework, ‘PerfectGPT,’ and highlight Beautiful AI's four core pillars: Beauty AI, Fashion AI, Skin AI, and Generative AI. This month, the company announced that Ms. Alice H. Chang, the Chairwoman, CEO, and controlling shareholder, purchased 597,256 Class A ordinary shares in the open market at an average price of $2.36 per share under a Rule 10b5-1 trading plan. The Board believes this acquisition demonstrates Ms. Chang's strong confidence in the company's prospects and growth potential, as well as her long-term commitment. As we await further updates from the company, we will be monitoring the $1.70 support level and watching for a potential resistance break at $2.00 for possible upward momentum.

--

Nukkleus Inc. (NASDAQ: NUKK) - Nukkleus Inc. shares ended last week's trading session up 1% at $0.85. In February, the company announced the signing of a term sheet to acquire Mercury Global, a leading cross-border payments firm operating in London and South Africa. This strategic move aims to strengthen Nukkleus' presence in the dynamic cross-border payments sector. Under the proposed agreement, Nukkleus will acquire all issued share capital of Mercury Global, with the purchase price settled in a combination of Nukkleus common stock and cash. The deal includes an initial equity issue at closing, followed by additional earn-out payments in equity and cash, contingent upon meeting milestones related to business volume, client growth, employee retention, banking relationships, and technology integration. The transaction is subject to relevant regulatory approvals in the UK. Emil Assentato, CEO of Nukkleus, expressed enthusiasm about the acquisition's strategic benefits: "This acquisition demonstrates our commitment to enhancing our cross-border payment capabilities. Mercury Global's strong regulatory standing in the UK, its strategic presence in South Africa as a gateway to the SADC market, and its robust banking partnerships, provide invaluable additions to Nukkleus. We are poised to unlock new revenue streams through increased volumes and an expanded service offering." As we await further updates from the company, we will be monitoring the resistance area at $0.90 for possible upward momentum.

--

BioVie Inc. (NASDAQ: BIVI) - BioVie Inc. shares ended last week's trading session down 5% at $0.46. At the end of April, the company announced a clinical trial award of up to $13.1 million from the U.S. Department of Defense (DOD), granted through the Peer Reviewed Medical Research Program (PRMRP) of the Congressionally Directed Medical Research Programs (CDMRP). This award provides up to two years of non-dilutive funding for a Phase 2b clinical trial assessing the company's anti-inflammatory and insulin sensitizer candidate, bezisterim (NE3107), for treating neurological symptoms associated with long COVID. The preliminary plan for this randomized (1:1), placebo-controlled, multicenter trial is to evaluate the safety and tolerability of three months of bezisterim treatment, along with its effectiveness in reducing long COVID-related neurological symptoms, in approximately 200 patients. Last week, the company announced a webinar for investors on June 26, 2024, at 4:15 p.m. ET. Hosted by RedChip Companies, this exclusive event will feature Cuong Do, President and CEO of BioVie, who will discuss the company's late-stage clinical programs targeting unmet medical needs in neurodegeneration and liver disease. BioVie's strategic priorities include launching a Phase 2b trial for Parkinson's in Fall 2024, initiating a Phase 3 trial for Alzheimer's in mid-2025 with a new once-daily formulation of bezisterim, continuing partnership discussions for bezisterim's geographic rights, and commencing a Phase 3 trial for ascites upon identifying a suitable partner. As we await further updates, we will be monitoring for a resistance break at the $0.48 level.

--

Biodexa Pharmaceuticals plc (NASDAQ: BDRX) - Biodexa Pharmaceuticals plc shares ended last week's trading session slightly up at $0.98. This month, the company announced promising Phase 2 results for its newly in-licensed drug eRapa, aimed at treating familial adenomatous polyposis (FAP), a primarily genetic disease of the lower GI tract for which surgery is currently the only remedy. In a clinical trial involving 30 adult patients, three groups received the same dose of eRapa but with different regimens over 12 months. Safety, tolerability, and changes in polyp burden (measured by the sum of polyp diameters) were evaluated using endoscopic exams. Biodexa claims that no drug has shown such promise in halting the progression of this disease. The company plans to announce the 12-month results of the Phase 2 trial at the InSIGHT scientific conference in Barcelona on June 19-22, 2024. Carol Burke, MD, the Principal Investigator, will present the six- and 12-month data (NCT04230499) in an oral presentation at the conference on June 22, 2024. As we await further updates from the company, we will be watching for a potential resistance break at the $1.05 level. We would also like to highlight that the company filed an F-1 this month, which is not yet in effect.

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.